Legacy Edge Advisors LLC Acquires New Shares in Thermo Fisher Scientific Inc. $TMO

Legacy Edge Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 1,581 shares of the medical research company’s stock, valued at approximately $916,000.

Several other hedge funds have also added to or reduced their stakes in the business. Benjamin Edwards Inc. boosted its position in Thermo Fisher Scientific by 1.2% during the 4th quarter. Benjamin Edwards Inc. now owns 12,594 shares of the medical research company’s stock worth $7,299,000 after buying an additional 154 shares during the period. Pines Wealth Management LLC lifted its holdings in Thermo Fisher Scientific by 16.1% during the 4th quarter. Pines Wealth Management LLC now owns 3,239 shares of the medical research company’s stock worth $1,877,000 after buying an additional 449 shares during the period. Sandro Wealth Management LLC acquired a new position in Thermo Fisher Scientific during the 4th quarter worth about $2,089,000. Artemis Investment Management LLP lifted its holdings in Thermo Fisher Scientific by 2.1% during the 4th quarter. Artemis Investment Management LLP now owns 62,173 shares of the medical research company’s stock worth $36,026,000 after buying an additional 1,300 shares during the period. Finally, SevenBridge Financial Group LLC lifted its holdings in Thermo Fisher Scientific by 1.4% during the 4th quarter. SevenBridge Financial Group LLC now owns 6,117 shares of the medical research company’s stock worth $3,833,000 after buying an additional 83 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Down 2.0%

Thermo Fisher Scientific stock opened at $469.39 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99. The firm’s fifty day moving average is $496.11 and its 200 day moving average is $547.87. The company has a market capitalization of $174.43 billion, a PE ratio of 25.80, a PEG ratio of 2.08 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. During the same quarter in the previous year, the company earned $5.15 EPS. Thermo Fisher Scientific’s quarterly revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were paid a dividend of $0.47 per share. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend was Friday, March 13th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.34%.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. This represents a 3.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 5,800 shares of company stock worth $2,963,544. 0.33% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

TMO has been the topic of several recent research reports. UBS Group reaffirmed a “neutral” rating and set a $615.00 target price on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. DZ Bank initiated coverage on shares of Thermo Fisher Scientific in a research report on Friday, March 27th. They issued a “buy” rating and a $610.00 price target on the stock. Finally, Citigroup boosted their price target on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $623.05.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.